Rifampin Capsules USP 300mg — Class II drug recall D-0284-2024
Terminated recall by Lupin Pharmaceuticals Inc., reported 2024-02-07. Subpotent Drug and Failed Impurities/Degradation Specifications
| Recall number | D-0284-2024 |
|---|---|
| Product type | Drug |
| Classification | Class II |
| Status | Terminated |
| Voluntary or mandated | Voluntary |
| Recalling firm | Lupin Pharmaceuticals Inc., Baltimore, MD, United States |
| Recall initiated | 2024-01-05 |
| Classified | 2024-01-30 |
| Reported by FDA | 2024-02-07 |
| Terminated | 2024-08-27 |
| Reason classes | potency, specification failure |
| NDC | 68180-0658, 68180-0658-01, 68180-0658-06, 68180-0659, 68180-0659-01, 68180-0659-06, 68180-0659-07 |
| Expiration dates | 2024-01 |
Product
Rifampin Capsules USP 300mg, 30-count bottle, Rx Only, Manufactured for: Lupin Pharmaceuticals, Inc. Baltimore, Maryland 21202 United States, Manufactured Lupin Limited, Aurangabad 431 210 INDIA, NDC 68180-659-06
Reason for recall
Subpotent Drug and Failed Impurities/Degradation Specifications
Machine access
This record, with every extracted code, the verbatim FDA record and provenance, is available from the recall API: GET https://api.data.aroqon.com/v1/recalls/D-0284-2024. Look up any UPC, UDI, NDC or lot with /v1/recalls/lookup?code=…. API docs · free and paid keys.
Source: U.S. Food and Drug Administration enforcement report via openFDA (CC0). Structured by Data Foundry (recall-structuring@2); last changed 2026-09-26. Not affiliated with or endorsed by FDA. Not medical or legal advice.